Cochrane Review Group

Gut

172 systematic reviews in Gut ask 2,395 questions. 17.5% have no studies to answer them, 34.3% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

172

Questions

2,395

current versions

No studies

17.5%

Moderate or high

20.6%

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gut

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.79 [0.37, 1.68]	1 study · 140 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 1.01 [0.65, 1.57]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.94 [0.7, 1.25]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.77 [0.3, 1.97]	1 study · 53 participants	Very low
Infliximab vs placebo Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.59 [0.37, 0.96]	1 study · 73 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.68 [0.29, 1.59]	1 study · 73 participants	Very low
Infliximab vs adalimumab Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.1 [0.01, 0.72]	1 study · 73 participants	Very low
Infliximab vs adalimumab Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.09 [0.01, 1.54]	1 study · 73 participants	Very low

Reviews 172

Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis

Nguyen, N, Zhang, B, et al. · Cochrane Database of Systematic Reviews · 2019

Gut

Thinnest evidence

Reviews 172

Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis

Probiotics for the prevention of pediatric antibiotic‐associated diarrhea

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease

Homeopathy for treatment of irritable bowel syndrome

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease

N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication

Biofeedback for treatment of irritable bowel syndrome

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease

The impact of surgical therapies for inflammatory bowel disease on female fertility

Antibiotics for induction and maintenance of remission in Crohn's disease

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease

Dietary interventions for induction and maintenance of remission in inflammatory bowel disease

Adalimumab for induction of remission in Crohn's disease

Certolizumab pegol for induction of remission in Crohn's disease

Continuous veno‐venous hemofiltration for severe acute pancreatitis

Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis

Enteral nutritional therapy for induction of remission in Crohn's disease

Enteral nutrition for maintenance of remission in Crohn's disease

Natalizumab for induction of remission in Crohn's disease

Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units

Prokinetics for functional dyspepsia

Low dose naltrexone for induction of remission in Crohn's disease

Chemotherapy and radiotherapy for advanced pancreatic cancer

Non‐invasive diagnostic tests for Helicobacter pylori infection

Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction